Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network)

• Published in: The American journal of cardiology 2016-06, Vol.117 (12), p.1904-1910
• Main Authors: Siontis, Konstantinos C., MD, Barsness, Gregory W., MD, Lennon, Ryan J., MS, Holmen, Jody L., MBA, RN, Wright, R. Scott, MD, Bell, Malcolm R., MD, Gersh, Bernard J., MB, ChB, DPhil
• Format: Article
• Language: English
• Subjects: Cardiovascular; Clinical outcomes; Confidence intervals; Electrocardiography; Female; Fibrinolytic Agents - therapeutic use; Follow-Up Studies; Health risk assessment; Heart attacks; Hospital Mortality - trends; Hospitalization; Humans; Intubation; Laboratories; Male; Medical imaging; Middle Aged; Minnesota - epidemiology; Mortality; Percutaneous Coronary Intervention - methods; Practice Guidelines as Topic; Registries; Retrospective Studies; Review boards; ST Elevation Myocardial Infarction - epidemiology; ST Elevation Myocardial Infarction - therapy; Survival Rate - trends; Thrombolytic Therapy - methods; Time Factors; Treatment Outcome; Variables
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2016.03.036

The effectiveness of a pharmacoinvasive strategy consisting of fibrinolysis and transfer for percutaneous coronary intervention (PCI) compared to primary PCI (PPCI) in patients presenting to non–PCI-capable hospitals with ST-elevation myocardial infarction (STEMI) is not well defined. We analyzed data from the Mayo Clinic STEMI database of patients treated with a pharmacoinvasive strategy (favored in those presenting early after symptom onset) or PPCI in a regional STEMI network from 2004 to 2012. A total of 364 and 1,337 patients were included in the pharmacoinvasive and PPCI groups, respectively. Patients in the PPCI group were older and more frequently had cardiogenic shock at the time of presentation (12.1% vs 7.7%, p = 0.018). Death from any cause occurred in 58 (16%) and 314 (23%) patients in the pharmacoinvasive and PPCI groups, respectively (median follow-up 3.9 and 4.4 years, respectively). In multivariate analyses adjusting for age, gender, and other variables for which the 2 groups differed at baseline, there was no significant difference between the 2 strategies for 30-day (hazard ratio 0.66, 95% confidence interval 0.36 to 1.21) or overall mortality (hazard ratio 0.84, 95% confidence interval 0.63 to 1.12). Shorter door-to-balloon time was associated with increased effectiveness of PPCI (p for trend = 0.015), but there was no difference between the 2 strategies even when considering only the patients with door-to-balloon time in the lowest quartile. In conclusion, fibrinolysis followed by transfer for PCI represents a reasonable alternative when PPCI is not readily available especially in patients presenting early after symptom onset.